FDA approves nivolumab for metastatic renal cell carcinoma

The Food and Drug Administration has approved nivolumab for the treatment of patients with metastatic renal cell carcinoma who have previously received antiangiogenic therapy, expanding on approval...

Field of Interest: Oncology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.